Summary:

 Senate Bill 207 (SB207) relating to insurance by modifying the Prior Authorization Act to add more classes of drug that are not subject to prior authorization or step therapy protocols. 

Legislation Overview:

  Senate Bill207 (SB207)by purpose is to add more classes of drug that would not be subject to prior authorization or step therapy. This would be a modification of the Prior Authorization Act that would add on-label and off-label use of a drug for rare diseases and would prohibit prior authorization or step therapy requirements from insurers. 
Section 59A-22B-8 NMSA 1978 (being Laws 2023, Chapter 114, Section 13, will add a new Subsection C to read: “For the purposes of this Section, "rare disease" means a disease or medical condition that affects fewer than two hundred thousand people in the United States. "
Section 59A-22B-8 NMSA 1978 (being Laws 2023, Chapter 114,refers to the prohibition of prior authorization and step therapy in statute.